ZA200804572B - Protein-based delivery system for overcoming resistance in tumour cells - Google Patents

Protein-based delivery system for overcoming resistance in tumour cells

Info

Publication number
ZA200804572B
ZA200804572B ZA200804572A ZA200804572A ZA200804572B ZA 200804572 B ZA200804572 B ZA 200804572B ZA 200804572 A ZA200804572 A ZA 200804572A ZA 200804572 A ZA200804572 A ZA 200804572A ZA 200804572 B ZA200804572 B ZA 200804572B
Authority
ZA
South Africa
Prior art keywords
protein
delivery system
tumour cells
based delivery
overcoming resistance
Prior art date
Application number
ZA200804572A
Other languages
English (en)
Inventor
Dreis Sebastian
Langer Klaus
Kreuter Joerg
Michaels Martin
Cinatl Jindrich
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of ZA200804572B publication Critical patent/ZA200804572B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200804572A 2005-12-27 2008-05-23 Protein-based delivery system for overcoming resistance in tumour cells ZA200804572B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005062440A DE102005062440B4 (de) 2005-12-27 2005-12-27 Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen

Publications (1)

Publication Number Publication Date
ZA200804572B true ZA200804572B (en) 2009-03-25

Family

ID=38110688

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804572A ZA200804572B (en) 2005-12-27 2008-05-23 Protein-based delivery system for overcoming resistance in tumour cells

Country Status (14)

Country Link
US (1) US20090181090A1 (xx)
EP (1) EP1965769A2 (xx)
JP (1) JP2009521515A (xx)
KR (1) KR20080081080A (xx)
CN (1) CN101346131A (xx)
AU (1) AU2006331030A1 (xx)
BR (1) BRPI0620800A2 (xx)
CA (1) CA2631003A1 (xx)
DE (1) DE102005062440B4 (xx)
IL (1) IL192343A0 (xx)
NZ (1) NZ569898A (xx)
RU (1) RU2404916C2 (xx)
WO (1) WO2007073932A2 (xx)
ZA (1) ZA200804572B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811175D0 (en) * 2008-06-18 2008-07-23 Prendergast Patrick T Anti-tumour compositions and methods
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US20120263739A1 (en) * 2009-11-13 2012-10-18 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
CN103202812B (zh) * 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
JP6320042B2 (ja) 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
CN102846562B (zh) * 2012-09-28 2014-11-26 山东大学 一种半乳糖介导的冬凌草甲素白蛋白纳米粒及其制备方法
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
CN103275965A (zh) * 2013-05-22 2013-09-04 武汉理工大学 一种自恢复多功能软包埋细胞固载体系及其制备方法
CN103611169A (zh) * 2013-12-02 2014-03-05 东南大学 具有靶向性的免疫磁性白蛋白纳米球及制备方法
AU2015258891A1 (en) * 2014-05-16 2016-12-01 Dana-Farber Cancer Institute, Inc. Protein-based particles for drug delivery
WO2016020697A1 (en) * 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
US20160199497A1 (en) * 2014-09-10 2016-07-14 Purdue Research Foundation Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy
CN104211815B (zh) * 2014-09-12 2017-06-06 华东理工大学 一种铁蛋白重链亚基纳米载药系统及其制备方法与应用
CN104382854A (zh) * 2014-10-09 2015-03-04 唐春林 一种多柔比星脂质微泡及其制备方法
CN104324005A (zh) * 2014-10-09 2015-02-04 唐春林 一种争光霉素脂质微泡及其制备方法
CN104382904B (zh) * 2014-10-09 2018-02-13 唐春林 一种长春新碱脂质微泡及其制备方法
US10265413B2 (en) 2014-11-05 2019-04-23 University Of The Sciences In Philadelphia High molecular weight biodegradable gelatin-doxorubicin conjugate
MA41866A (fr) * 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN105343005A (zh) * 2015-11-06 2016-02-24 中国药科大学 一种新型中药纳米粒口服吸收增强技术
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) * 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CN108741097A (zh) * 2018-05-17 2018-11-06 华南理工大学 一种蛋白自组装包埋难溶活性物质纳米制品及其制备方法
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
CN110051653A (zh) * 2019-06-03 2019-07-26 辽宁大学 一种制备荜茇酰胺白蛋白纳米粒及冻干粉的方法
CN111249254B (zh) * 2020-01-16 2022-02-18 暨南大学 一种包载黄芩苷的叶酸偶联白蛋白纳米粒的制备方法和应用
US20230135752A1 (en) * 2020-03-27 2023-05-04 PhotoQ3 Inc. Medicament for killing tumor cells
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147976T1 (de) * 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
AU4373499A (en) * 1999-06-02 2000-12-28 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
DE102004011776A1 (de) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen

Also Published As

Publication number Publication date
BRPI0620800A2 (pt) 2016-11-01
US20090181090A1 (en) 2009-07-16
NZ569898A (en) 2011-06-30
WO2007073932A3 (de) 2007-09-27
RU2404916C2 (ru) 2010-11-27
JP2009521515A (ja) 2009-06-04
DE102005062440A1 (de) 2007-07-05
EP1965769A2 (de) 2008-09-10
DE102005062440B4 (de) 2011-02-24
CA2631003A1 (en) 2007-07-05
CN101346131A (zh) 2009-01-14
KR20080081080A (ko) 2008-09-05
RU2008130167A (ru) 2010-01-27
WO2007073932A2 (de) 2007-07-05
IL192343A0 (en) 2009-02-11
AU2006331030A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
ZA200804572B (en) Protein-based delivery system for overcoming resistance in tumour cells
IL206347A0 (en) Redundancies and flows in vehicles
EP2255190A4 (en) FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER
GB2449337B (en) Novel borozirconate systems in completion systems
ZA201001933B (en) Cell-permeabilising peptides and polypeptides for microbial cells
ZA200905879B (en) Arabinoxylo-oligosaccharides in beer
GB0725321D0 (en) Delivery vehicles
EP2193805A4 (en) IMMUNOSUPPRESSION WEANING AGENT COMPRISING A TUMOR CELL AND ANTI-TUMOR AGENT USING THE SAME
IL198354A0 (en) Genetic variations associated with tumors
GB0815340D0 (en) Improvements in MBMS
GB0714021D0 (en) Improvements in anode materials
GB0712040D0 (en) Improvements in combine harvesters
AP2008004572A0 (en) Cell classification system
EP1963595A4 (en) ORDER IN CONNECTION WITH THE ROOF
GB0700221D0 (en) Improvements in an ehspa architecture
GB0616529D0 (en) Improvements in user-propelled vehicles
GB0509566D0 (en) Improvements in pseudostereoscopic convesion systems
GB0516501D0 (en) Improvements in chemotherapy
GB0513683D0 (en) Advanced parcel delivery system
GB0718539D0 (en) Improvements in cancer chemotherapy
AU2007901945A0 (en) Improvements in animal transport trailers
AU2007903454A0 (en) Improvements in Ironmongery
GB0706911D0 (en) Improvements in or relating to tilting vehicles
GB0614685D0 (en) Improvements in Anode Materials
GB0613681D0 (en) Improvements in anode materials